Patents by Inventor Emily A. STEIN
Emily A. STEIN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20180143188Abstract: Disclosed is a covalently-linked multilayered three-dimensional matrix comprising capture molecules, linkers and spacers (referred to as a Molecular Net) for specific and sensitive analyte capture from a sample. Also disclosed herein is a Molecular Net comprising covalently-linked multilayered three-dimensional matrix comprising more than one type of capture molecule and more than one type of linker and may comprise one or more spacer for specific and sensitive capture of more than one type of analyte from a sample. A Molecular Net may comprise a pseudorandom nature. Use of various capture molecules, linkers and spacers in a Molecular Net may confer unique binding properties to a Molecular Net. Porosity, binding affinity, size exclusion abilities, filtration abilities, concentration abilities and signal amplification abilities of a Molecular Net may be varied and depend on the nature of components used in its fabrication.Type: ApplicationFiled: July 6, 2017Publication date: May 24, 2018Applicant: Sevident, Inc.Inventors: Emily A. STEIN, Bruce PHELPS, Robert PLACE, Dina UZRI
-
Patent number: 9910040Abstract: A molecular net formed as a branched pseudorandom copolymer including two broad classes of subunits: capture agents and linking agents. The subunits self-assemble to form a structure capable of binding to predetermined targets. The binding can then be detected.Type: GrantFiled: July 9, 2013Date of Patent: March 6, 2018Assignee: Sevident, Inc.Inventors: Emily A. Stein, Michael A. Evans
-
Publication number: 20180050082Abstract: The present invention relates to the use of serpins, including A1AT, its derivatives and analogs thereof, in the prevention or treatment of neuroinflammatory diseases. In particular embodiments, the invention relates to the combination of A1AT and another anti-inflammatory therapeutic compound. The present invention further relates to methods for administering said A1AT combination.Type: ApplicationFiled: March 9, 2016Publication date: February 22, 2018Applicant: Anvil Biosciences, LLCInventors: Jack Tzu-Chiao Lin, Emily A. Stein
-
Patent number: 9733242Abstract: Disclosed is a covalently-linked multilayered three-dimensional matrix comprising capture molecules, linkers and spacers (referred to as a Molecular Net) for specific and sensitive analyte capture from a sample. Also disclosed herein is a Molecular Net comprising covalently-linked multilayered three-dimensional matrix comprising more than one type of capture molecule and more than one type of linker and may comprise one or more spacer for specific and sensitive capture of more than one type of analyte from a sample. A Molecular Net may comprise a pseudorandom nature. Use of various capture molecules, linkers and spacers in a Molecular Net may confer unique binding properties to a Molecular Net. Porosity, binding affinity, size exclusion abilities, filtration abilities, concentration abilities and signal amplification abilities of a Molecular Net may be varied and depend on the nature of components used in its fabrication.Type: GrantFiled: March 14, 2014Date of Patent: August 15, 2017Assignee: Sevident, Inc.Inventors: Emily Stein, Bruce Phelps, Robert Place, Dina Uzri
-
Publication number: 20170056621Abstract: Methods for treating inflammatory pulmonary diseases by administering to the patient an effective amount of one or more pharmaceutical agents are disclosed. The pharmaceutical agents administered can include antibiotics, steroids, NSAIDs, DMARDs, growth factor receptor inhibitors, PI3K inhibitors, neurotransmitter receptor inhibitors, or protease inhibitors. The dose administered is effective to suppress or prevent initiation, progression, or relapses of disease, including the progression of established disease. The pharmaceutical agent is administered to a patient determined to have the disease and at an amount effective to suppress or prevent activity of the disease. The pharmaceutical agent is administered using a transtracheal, transbronchial, or transvascular drug delivery catheter. The pharmaceutical agent can be administered to the patient's pulmonary tissue to suppress reactions in response to bronchial thermoplasty either before, during, or after bronchial thermoplasty.Type: ApplicationFiled: August 31, 2016Publication date: March 2, 2017Inventors: Emily STEIN, Kirk Patrick SEWARD
-
Publication number: 20160030327Abstract: Non-toxic consumable compositions and formulations having chelator and base are disclosed with synergistic effects on microbial metabolism and/or growth and/or pathogenic effectors and their use to promote and maintain health in mammals. The non-toxic consumable compositions have more than one chelator and/or more than one base. Methods for selecting said chelator and base composition and methods for detecting conditions in which selected compositions may be used are also disclosed. The synergistic compositions and methods can be used for maintaining health, promoting health and treating diseases.Type: ApplicationFiled: March 12, 2014Publication date: February 4, 2016Inventor: Emily A. STEIN
-
Publication number: 20160008387Abstract: Agents and devices for affecting nerve function are described. In some variations, a combination of agents, e.g., a cardiac glycoside, an ACE inhibitor, and an NSAID are delivered to affect nerve function. The agent may be delivered locally in a site-specific manner to a targeted nerve or portion of a nerve. For example, the agent may be delivered locally to the renal nerves to impair their function and treat hypertension. One variation of a delivery device includes one or more needle housings supported by a balloon. A delivery needle is slidably disposed within a needle lumen of each needle housing.Type: ApplicationFiled: May 7, 2013Publication date: January 14, 2016Inventors: Emily A. Stein, Christina D. Swanson, Michael A. Evans, Kondapavulur T. Venkateswara-Rao
-
Publication number: 20150202220Abstract: Agents, methods, and devices for affecting nerve function are described. One embodiment of an agent includes a cardiac glycoside, an ACE inhibitor, and an NSAID. The agent may be delivered locally in a site-specific manner to a targeted nerve or portion of a nerve. For example, the agent may be delivered locally to the renal nerves to impair their function and treat hypertension. One embodiment of a delivery device includes one or more needle housings supported by a balloon. A delivery needle is slidably disposed within a needle lumen of each needle housing.Type: ApplicationFiled: October 25, 2012Publication date: July 23, 2015Applicant: Northwind Medical, Inc.Inventors: Emily A. Stein, Christina D. Swanson, Michael A. Evans, Kondapavulur T. Venkateswara-Rao
-
Patent number: 9056184Abstract: Various agents are described to denerve, modulate, or otherwise affect the renal nerves and other neural tissue. Also, various delivery devices are described to deliver an agent locally to the renal nerves. The delivery devices are positioned in the renal artery and penetrate into the wall of the renal artery to deliver the agent to the renal nerves. The delivery devices may be used to deliver the agent according to longitudinal position, radial position, and depth of the renal nerves relative to the renal artery. In addition, various methods are described to denervate, modulate, or otherwise affect the renal nerves and other neural tissue.Type: GrantFiled: April 28, 2011Date of Patent: June 16, 2015Assignee: Northwind Medical, Inc.Inventors: Emily A. Stein, Kondapavulur T. Venkateswara-Rao, Michael A. Evans
-
Publication number: 20150132409Abstract: Agents and devices for affecting nerve function are described. In some variations, a combination of agents, e.g., a cardiac glycoside, an ACE inhibitor, and an NSAID are delivered to affect nerve function. The agent may be delivered locally in a site-specific manner to a targeted nerve or portion of a nerve. For example, the agent may be delivered locally to the renal nerves to impair their function and treat hypertension. One variation of a delivery device includes one or more needle housings supported by a balloon. A delivery needle is slidably disposed within a needle lumen of each needle housing.Type: ApplicationFiled: May 7, 2013Publication date: May 14, 2015Inventors: Emily A. Stein, Christina D. Swanson, Michael A. Evans, Kondapavulur T. Venkateswara-Rao
-
Patent number: 8975233Abstract: Various agents are described to denerve, modulate, or otherwise affect the renal nerves and other neural tissue. Also, various delivery devices are described to deliver an agent locally to the renal nerves. The delivery devices are positioned in the renal artery and penetrate into the wall of the renal artery to deliver the agent to the renal nerves. The delivery devices may be used to deliver the agent according to longitudinal position, radial position, and depth of the renal nerves relative to the renal artery. In addition, various methods are described to denervate, modulate, or otherwise affect the renal nerves and other neural tissue.Type: GrantFiled: January 26, 2011Date of Patent: March 10, 2015Assignee: Northwind Medical, Inc.Inventors: Emily A. Stein, Kondapavulur T. Venkateswara-Rao, Michael A. Evans
-
Publication number: 20140373920Abstract: Presented herein is a voltaic cell containing light harvesting antennae or other biologically-based electron generating structures optionally in a microbial population, an electron siphon population having electron conductive properties with individual siphons configured to accept electrons from the light harvesting antennae and transport the electrons to a current collector, an optional light directing system (e.g., a mirror), and a regulator having sensing and regulatory feedback properties for the conversion of photobiochemical energy and biochemical energy to electricity. Also presented herein is a voltaic cell having electricity-generating abilities in the absence of light. Also presented herein is the use of the voltaic cell in a solar panel.Type: ApplicationFiled: June 25, 2014Publication date: December 25, 2014Inventor: Emily A. Stein
-
Publication number: 20140315759Abstract: Disclosed is a covalently-linked multilayered three-dimensional matrix comprising capture molecules, linkers and spacers (referred to as a Molecular Net) for specific and sensitive analyte capture from a sample. Also disclosed herein is a Molecular Net comprising covalently-linked multilayered three-dimensional matrix comprising more than one type of capture molecule and more than one type of linker and may comprise one or more spacer for specific and sensitive capture of more than one type of analyte from a sample. A Molecular Net may comprise a pseudorandom nature. Use of various capture molecules, linkers and spacers in a Molecular Net may confer unique binding properties to a Molecular Net. Porosity, binding affinity, size exclusion abilities, filtration abilities, concentration abilities and signal amplification abilities of a Molecular Net may be varied and depend on the nature of components used in its fabrication.Type: ApplicationFiled: March 14, 2014Publication date: October 23, 2014Applicant: Sevident, Inc.Inventors: Emily STEIN, Bruce PHELPS, Robert PLACE, Dina UZRI
-
Publication number: 20140288015Abstract: Various methods and devices are described for affecting nerve function in the carotid body, renal nerves, and other nerves. Syringes, endovascular catheters, drug-eluting balloons, drug-eluting stents, and agent delivery patches are used to deliver a neuromodulatory agent to one or more nerves in order to treat a disease state.Type: ApplicationFiled: March 17, 2014Publication date: September 25, 2014Inventors: Kondapavulur T. VENKATESWARA-RAO, Emily A. STEIN, Michael A. EVANS, Mark H. WHOLEY
-
Publication number: 20140080119Abstract: A molecular net formed as a branched pseudorandom copolymer including two broad classes of subunits: capture agents and linking agents. The subunits self-assemble to form a structure capable of binding to predetermined targets. The binding can then be detected.Type: ApplicationFiled: July 9, 2013Publication date: March 20, 2014Inventors: Emily A. STEIN, Michael A. EVANS
-
Publication number: 20140011755Abstract: The invention provides methods for treating inflammatory and autoimmune diseases by administering to the subject an effective amount of a cardiac glycoside, where the dose is effective to suppress or prevent initiation, progression, or relapses of the disease, including the progression of established disease. In some embodiments, the methods of the invention comprise administering to a subject determined to have rheumatoid arthritis or systemic lupus, or a pre-clinical disease state thereof, an effective amount of a cardiac glycoside, to suppress or prevent activity of the disease. In other embodiments, the methods of the invention comprise administering to a subject determined to have insufficient endogenous cardiac glycosides, an effective amount as a supplement to counteract the effects of cardiac glycoside deficiency.Type: ApplicationFiled: December 13, 2011Publication date: January 9, 2014Applicants: Department of Veterans Affairs, The Board of Trustees of the Leland Stanford Junior UniversityInventors: Emily A. Stein, William H. Robinson, Ricardo T. Paniagua
-
Publication number: 20130052653Abstract: The invention provides “molecular nets” which may be used in diagnostic and other applications to detect analytes in a sample. A molecular net is a branched pseudorandom copolymer comprising two broad classes of subunits: capture agents and linking agents. The subunits self-assemble to form a structure capable of binding to predetermined targets. The binding can then be detected.Type: ApplicationFiled: November 24, 2010Publication date: February 28, 2013Applicant: ARGOS, INC.Inventors: Emily A. Stein, Michael A. Evans
-
Publication number: 20120108517Abstract: Various agents are described to denerve, modulate, or otherwise affect the renal nerves and other neural tissue. Also, various delivery devices are described to deliver an agent locally to the renal nerves. The delivery devices are positioned in the renal artery and penetrate into the wall of the renal artery to deliver the agent to the renal nerves. The delivery devices may be used to deliver the agent according to longitudinal position, radial position, and depth of the renal nerves relative to the renal artery. In addition, various methods are described to denervate, modulate, or otherwise affect the renal nerves and other neural tissue.Type: ApplicationFiled: April 28, 2011Publication date: May 3, 2012Inventors: Michael A. EVANS, Kondapavulur T. VENKATESWARA-RAO, Emily A. STEIN
-
Publication number: 20110182912Abstract: Various agents are described to denerve, modulate, or otherwise affect the renal nerves and other neural tissue. Also, various delivery devices are described to deliver an agent locally to the renal nerves. The delivery devices are positioned in the renal artery and penetrate into the wall of the renal artery to deliver the agent to the renal nerves. The delivery devices may be used to deliver the agent according to longitudinal position, radial position, and depth of the renal nerves relative to the renal artery. In addition, various methods are described to denervate, modulate, or otherwise affect the renal nerves and other neural tissue.Type: ApplicationFiled: January 26, 2011Publication date: July 28, 2011Inventors: Michael A. EVANS, Kondapavulur T. VENKATESWARA-RAO, Emily A. STEIN
-
Publication number: 20110184337Abstract: Various delivery devices are described to deliver an agent locally to the renal nerves. The delivery devices are positioned in the renal artery and penetrate into the wall of the renal artery to deliver the agent to the renal nerves. The delivery devices may be used to deliver the agent according to longitudinal position, radial position, and depth of the renal nerves relative to the renal artery. In addition, various methods are described to denervate, modulate, or otherwise affect the renal nerves and other neural tissue. Also, various agents are described to denerve, modulate, or otherwise affect the renal nerves and other neural tissue.Type: ApplicationFiled: January 26, 2011Publication date: July 28, 2011Inventors: Michael A. EVANS, Kondapavulur T. VENKATESWARA-RAO, Emily A. STEIN